Cargando…

Patterns, Predictors, and Prognostic Value of Skeletal Muscle Mass Loss in Patients with Locally Advanced Head and Neck Cancer Undergoing Cisplatin-Based Chemoradiotherapy

Low skeletal muscle mass (SMM) is associated with toxicities and decreased survival in head and neck cancer (HNC). Chemoradiotherapy (CRT) may exaggerate loss of SMM. We investigated the changes in SMM, their predictors, and prognostic impact of SMM in patients treated with CRT between 2012 and 2018...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chargi, Najiba, Wegner, Inge, Markazi, Navid, Smid, Ernst, de Jong, Pim, Devriese, Lot, de Bree, Remco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074083/ https://www.ncbi.nlm.nih.gov/pubmed/33919607 http://dx.doi.org/10.3390/jcm10081762

Ejemplares similares

The association of pretreatment low skeletal muscle mass with chemotherapy dose‐limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high‐dose cisplatin
por: Bril, Sandra I., et al.
Publicado: (2021)

Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol
por: Schaeffers, Anouk W. M. A., et al.
Publicado: (2023)

The Predictive Value of Low Skeletal Muscle Mass Assessed on Cross-Sectional Imaging for Anti-Cancer Drug Toxicity: A Systematic Review and Meta-Analysis
por: Huiskamp, Laura F. J., et al.
Publicado: (2020)

Association of low skeletal muscle mass and systemic inflammation with surgical complications and survival after microvascular flap reconstruction in patients with head and neck cancer
por: Chargi, Najiba, et al.
Publicado: (2022)

The predictive and prognostic value of low skeletal muscle mass for dose-limiting toxicity and survival in head and neck cancer patients receiving concomitant cetuximab and radiotherapy
por: Huiskamp, L. F. J., et al.
Publicado: (2020)

Arterial calcification on preoperative computed tomography imaging as a risk factor for pharyngocutaneous fistula formation after total laryngectomy
por: Bril, Sandra I., et al.
Publicado: (2021)

The association between skeletal muscle measures and chemotherapy‐induced toxicity in non‐small cell lung cancer patients
por: de Jong, Corine, et al.
Publicado: (2022)

Nutritional interventions in patients with head and neck cancer undergoing chemoradiotherapy: Current practice at the Dutch Head and Neck Oncology centres
por: Kok, Annemieke, et al.
Publicado: (2021)

Low skeletal muscle mass predicts frailty in elderly head and neck cancer patients
por: Meerkerk, C. D. A., et al.
Publicado: (2021)

Chemoradiotherapy With Generic Cisplatin Formulations for Head and Neck Cancers
por: Shimada, Rie, et al.
Publicado: (2018)

Sarcopenia is a prognostic factor for overall survival in elderly patients with head-and-neck cancer
por: Chargi, N., et al.
Publicado: (2019)

Low skeletal muscle mass is predictive of dose-limiting toxicities in head and neck cancer patients undergoing low-dose weekly cisplatin chemoradiotherapy
por: Becker, Jan-Niklas, et al.
Publicado: (2023)

Interobserver agreement of skeletal muscle mass measurement on head and neck CT imaging at the level of the third cervical vertebra
por: Bril, S. I., et al.
Publicado: (2019)

Comparison of vinorelbine with cisplatin in concomitant chemoradiotherapy in head and neck carcinoma
por: Devleena,, et al.
Publicado: (2010)

Diagnostic and Treatment-Related Challenges in Sinonasal Teratocarcinosarcoma: A Report of Three Cases
por: Scheurleer, W. F. Julius, et al.
Publicado: (2023)

The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis
por: de Ruiter, Emma J., et al.
Publicado: (2017)

The prognostic role of NK cells and their ligands in squamous cell carcinoma of the head and neck: a systematic review and meta-analysis
por: Bisheshar, Sangeeta K., et al.
Publicado: (2020)

Feasibility of a supervised and home‐based tailored exercise intervention in head and neck cancer patients during chemoradiotherapy
por: Kok, Annemieke, et al.
Publicado: (2022)

Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin
por: Cho, Hundo, et al.
Publicado: (2022)

Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin
por: Cho, Hundo, et al.
Publicado: (2022)

Progressive resistance training in head and neck cancer patients undergoing concomitant chemoradiotherapy
por: Lonkvist, Camilla K., et al.
Publicado: (2017)

Impact of Diabetes Mellitus on Head and Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy
por: Kuo, Hsuan-Chih, et al.
Publicado: (2020)

Chemoradiotherapy for Head and Neck Cancer
por: D’Onofrio, Ida, et al.
Publicado: (2023)

Cisplatin-Based Chemotherapy versus Cetuximab in Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer Treatment
por: Hu, Ming-Hung, et al.
Publicado: (2014)

Comparative analysis of cisplatin-induced nephrotoxicity in head and neck cancer and carcinoma cervix during concurrent chemoradiotherapy
por: Bagri, Puneet Kumar, et al.
Publicado: (2014)

Concurrent Chemoradiotherapy With Weekly Low-Dose Cisplatin for Japanese Patients With Head and Neck Squamous Cell Carcinoma
por: Shinohara, Shogo, et al.
Publicado: (2021)

Hematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab
por: Wu, Qiuji, et al.
Publicado: (2021)

Dual time point imaging in locally advanced head and neck cancer to assess residual nodal disease after chemoradiotherapy
por: Soffers, Frederik, et al.
Publicado: (2022)

Nutritional Interventions in Head and Neck Cancer Patients Undergoing Chemoradiotherapy: A Narrative Review
por: Bossola, Maurizio
Publicado: (2015)

First experiences with (177)Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer
por: Klein Nulent, Thomas J. W., et al.
Publicado: (2021)

Induction chemotherapy with paclitaxel, ifosfamide, and cisplatin followed by concurrent chemoradiotherapy for unresectable locally advanced head and neck cancer
por: Chitapanarux, I, et al.
Publicado: (2010)

Modified Weekly Cisplatin-Based Chemotherapy Is Acceptable in Postoperative Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer
por: Lu, Hsueh-Ju, et al.
Publicado: (2015)

Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting
por: Economopoulou, Panagiota, et al.
Publicado: (2019)

Qualitative and Quantitative Diagnosis in Head and Neck Cancer
por: López, Fernando, et al.
Publicado: (2021)

Prophylactic Swallow Therapy for Patients with Head and Neck Cancer Undergoing Chemoradiotherapy: A Randomized Trial
por: Messing, Barbara Pisano, et al.
Publicado: (2017)

Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck
por: Kim, J G, et al.
Publicado: (2005)

Nephrotoxicity as a Dose-Limiting Factor in a High-Dose Cisplatin-Based Chemoradiotherapy Regimen for Head and Neck Carcinomas
por: Hoek, Jantien, et al.
Publicado: (2016)

Phase II trial of chemoradiotherapy with S-1 plus cisplatin for unresectable locally advanced head and neck cancer (JCOG0706)
por: Tahara, Makoto, et al.
Publicado: (2015)

Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer
por: Szturz, Petr, et al.
Publicado: (2019)

Comparison of Carboplatin With 5-Fluorouracil vs. Cisplatin as Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Hanemaaijer, Saskia H., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_98rso50l08388k3t2p6rl12jja